Participant visits complete in phase 2b trial of CLS-AX for wet AMD
Click Here to Manage Email Alerts
Clearside Biomedical announced the completion of the final participant visit in its ODYSSEY phase 2b clinical trial of CLS-AX, an axitinib injectable suspension for neovascular age-related macular degeneration.
“We believe there is a compelling market opportunity for CLS-AX to provide patients and physicians with a potentially safer treatment option and reduced treatment burden using axitinib, the highly-potent tyrosine kinase inhibitor, combined with delivery into the suprachoroidal space using our patented SCS Microinjector,” George Lasezkay, PharmD, JD, Clearside’s president and CEO, said in a company press release.
The randomized, double-masked, multicenter ODYSSEY trial enrolled 60 participants with wet AMD who were randomly assigned to CLS-AX 1 mg, given via suprachoroidal injection, or aflibercept 2 mg, given via intravitreal injection. Over the 36-week trial, researchers assessed mean change from baseline in best-corrected visual acuity as well as changes in visual function and ocular anatomy, the need for supplemental treatment and treatment burden.
Topline results will be reported in early October 2024, the company said in the release.
Click Here to Manage Email Alerts